These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 36781239)

  • 1. [Efficacy and safety of neoadjuvant chemotherapy combined with PD-1 antibody for esophageal squamous cell carcinoma in the real world].
    Wu PY; Wang T; Chen BJ; Shi MK; Huang B; Wu ND; Qi L; Chang XF; Wang LF; Liu BR; Ren W
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):170-174. PubMed ID: 36781239
    [No Abstract]   [Full Text] [Related]  

  • 2. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.
    Xu X; Sun Z; Liu Q; Zhang Y; Shen L; Zhang C; Lin H; Hu B; Rong L; Chen H; Wang X; Zhao X; Bai YR; Ye Q; Ma X
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study.
    Guo Y; Xu X; Wang T; Liu Y; Gu D; Fang Y; Wang Q; Shi H; Wu D; Zhang Z; Zhou G; Ye J
    Int Immunopharmacol; 2024 Sep; 138():112558. PubMed ID: 38941666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study.
    Wang W; Yi Y; Jia Y; Dong X; Zhang J; Song X; Song Y
    Thorac Cancer; 2022 Mar; 13(6):824-831. PubMed ID: 35118824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment.
    Wang X; Ling X; Wang C; Zhang J; Yang Y; Jiang H; Xin Y; Zhang L; Liang H; Fang C; Zheng D; Zhu J; Ma J
    Cancer Immunol Immunother; 2023 Jun; 72(6):1619-1631. PubMed ID: 36583750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
    Ohnuma H; Sato Y; Hayasaka N; Matsuno T; Fujita C; Sato M; Osuga T; Hirakawa M; Miyanishi K; Sagawa T; Fujikawa K; Ohi M; Okagawa Y; Tsuji Y; Hirayama M; Ito T; Nobuoka T; Takemasa I; Kobune M; Kato J
    Cancer Sci; 2018 Nov; 109(11):3554-3563. PubMed ID: 30137686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy.
    Kong Y; Su M; Fang J; Chen M; Zheng C; Jiang Y; Tao K; Wang C; Qiu G; Ji Y; Wang Y; Yang Y
    Sci Rep; 2024 Jul; 14(1):16495. PubMed ID: 39019976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
    Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
    EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Efficacy of Taxol Plus Platinum (TP) Chemotherapy Combined with Delayed Administration of PD-1 Inhibitors in Patients with Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.
    Shen L; Chen Z; Zhang Z; Wu Y; Ren Y; Li Y; Li Y; Yin X; Han F; Chen Y
    Drug Des Devel Ther; 2024; 18():2761-2773. PubMed ID: 38979399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
    Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
    Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC.
    Li Y; Zhou A; Liu S; He M; Chen K; Tian Z; Li Y; Qin J; Wang Z; Chen H; Tian H; Yu Y; Qu W; Xue L; He S; Wang S; Bie F; Bai G; Zhou B; Yang Z; Huang H; Fang Y; Li B; Dai X; Gao S; He J
    BMC Med; 2023 Mar; 21(1):86. PubMed ID: 36882775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma.
    Yang W; Xing X; Yeung SJ; Wang S; Chen W; Bao Y; Wang F; Feng S; Peng F; Wang X; Chen S; He M; Zhang N; Wang H; Zeng B; Liu Z; Kidane B; Seder CW; Koyanagi K; Shargall Y; Luo H; Peng S; Cheng C
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study.
    Yu Y; Wu T; Gan W; Liu C; Zhang R; Zheng J; Xiong J; Chen J; Li J
    Clin Transl Oncol; 2024 Sep; 26(9):2360-2368. PubMed ID: 38602642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus.
    Yamagata Y; Saito K; Hirano K; Oya M
    World J Surg Oncol; 2020 Sep; 18(1):252. PubMed ID: 32962718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE).
    Yan X; Duan H; Ni Y; Zhou Y; Wang X; Qi H; Gong L; Liu H; Tian F; Lu Q; Sun J; Yang E; Zhong D; Wang T; Huang L; Wang J; Chaoyang Wang ; Wang Y; Wan Z; Lei J; Zhao J; Jiang T
    Int J Surg; 2022 Jul; 103():106680. PubMed ID: 35595021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Qian T; Liu D; Cao G; Chen Z; Zhang Q
    Technol Cancer Res Treat; 2024; 23():15330338241231610. PubMed ID: 38497137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study.
    Wang J; Zhang J; Gao J; Zhao M; Ma Z
    Adv Clin Exp Med; 2024 Jun; 33(6):573-581. PubMed ID: 37676100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial).
    Goto H; Oshikiri T; Kato T; Nagatani Y; Funakoshi Y; Koterazawa Y; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Minami H; Kakeji Y
    PLoS One; 2024; 19(4):e0299742. PubMed ID: 38635652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma.
    Chao L; Liu J; Chen Y; Fan Y; Guo S; Zhang S
    Thorac Cancer; 2024 Mar; 15(8):622-629. PubMed ID: 38316630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Lv H; Huang C; Li J; Zhang F; Gai C; Liu Z; Xu S; Wang M; Li Z; Tian Z
    Front Immunol; 2022; 13():1100750. PubMed ID: 36741358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.